Breast ductal carcinoma in situ with micro-invasion versus ductal carcinoma in situ: a comparative analysis of clinicopathological and mammographic findings

Zhang, M.; Lin, Qi; Su, Xiaohui; Cui, Cheng‐Bin; Bian, Tiantian; Wang, C.Q.; Zhao, Jun; Li, L.L.; Ma, Jinzhu; Huang, Junhai

doi:10.1016/j.crad.2021.04.011

Cited by 7 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…El CDIS se manifiesta en el 80% de las veces como microcalcificaciones, las de mayor VPP para malignidad son las finas pleomórficas hasta en un 29% y las finas lineales o finas ramificadas hasta en un 70%, generalmente asociado a un grado nuclear alto. Cuando se localizan microcalcificaciones, es de gran utilidad realizar complementos con conos de magnificación para caracterizar su morfología, distribución y densidad [32][33][34] . Es de suma importancia hacer estudio complementario con ultrasonido, en búsqueda de nódulos que se asocien a las microcalcificaciones o que se localicen dentro de los ductos, ya que de estos hallazgos dependerá el mejor método para realizar la biopsia con aguja de corte guiada por imagen.…”

Section: Discussionunclassified

Manifestaciones radiológicas del carcinoma ductal <i>in situ</i>. ¿Cómo lo diagnosticamos?

Domínguez-García,

Larios-Cruz,

Moguel-Molina

et al. 2023

ARM

View full text Add to dashboard Cite

Identificar los hallazgos radiológicos en sus diferentes modalidades de imagen del carcinoma ductal in situ (CDIS) de la mama. Material y métodos: Se hizo una búsqueda de información en PubMed con las palabras "breast" AND "ductal carcinoma in situ", eligiendo artículos de radiología para la obtención de información. Se realizó una búsqueda de imágenes radiológicas y reportes de patología del archivo clínico y radiológico digital del hospital. Resultados: Los hallazgos mastográficos del CDIS son microcalcificaciones en 80% de los casos, de tipo amorfas, pleomorfas, gruesas heterogéneas, finas ramificadas y finas lineales. El hallazgo más común por ultrasonido es el nódulo irregular, hipervascular, hipoecoico y sin sombra acústica posterior. En resonancia magnética y mastografía contrastada el hallazgo más frecuente es el realce no masa. Conclusiones: El CDIS es asintomático; el tamizaje es muy importante en su detección. La morfología, distribución y densidad de las microcalcificaciones sospechosas, motivan al radiólogo a solicitar imágenes adicionales, para categorizar el hallazgo y elegir el mejor método de guía de imagen para la realización de la biopsia.Palabras clave: Microcalcificaciones. BIRADS. Carcinoma ductal in situ (CDIS). Mamografía. HISTOPATOLOGÍALos patrones arquitectónicos son comedón, cribiforme, micropapilar, papilar y sólido 4 . Los CDIS micropapilar, cribiforme y papilar se consideran patrones de bajo grado. Los CDIS con características sólidas o de comedón se consideran patrones de alto grado y tiene más propensión a convertirse en carcinoma infiltrante 4 .El CDIS se clasifica en tres grados nucleares designados como bajo, intermedio o alto. El

show abstract

Section: Discussionunclassified

Manifestaciones radiológicas del carcinoma ductal <i>in situ</i>. ¿Cómo lo diagnosticamos?

Domínguez-García,

Larios-Cruz,

Moguel-Molina

et al. 2023

ARM

View full text Add to dashboard Cite

show abstract

“…In an invasive breast cancer, the cancerous cells spread to the ducts and possibly to the lymph nodes. Conversely, non-invasive cancer is confined to ducts or lobules where the cancer originated [ 40 ].…”

Section: Breast Cancer Symptoms and Diagnosismentioning

confidence: 99%

A Review of the Nucleic Acid-Based Lateral Flow Assay for Detection of Breast Cancer from Circulating Biomarkers at a Point-of-Care in Low Income Countries

et al. 2022

View full text Add to dashboard Cite

The current levels of breast cancer in African women have contributed to the high mortality rates among them. In South Africa, the incidence of breast cancer is also on the rise due to changes in behavioural and biological risk factors. Such low survival rates can be attributed to the late diagnosis of the disease due to a lack of access and the high costs of the current diagnostic tools. Breast cancer is asymptomatic at early stages, which is the best time to detect it and intervene to prevent high mortality rates. Proper risk assessment, campaigns, and access to adequate healthcare need to be prioritised among patients at an early stage. Early detection of breast cancer can significantly improve the survival rate of breast cancer patients, since therapeutic strategies are more effective at this stage. Early detection of breast cancer can be achieved by developing devices that are simple, sensitive, low-cost, and employed at point-of-care (POC), especially in low-income countries (LICs). Nucleic-acid-based lateral flow assays (NABLFAs) that combine molecular detection with the immunochemical visualisation principles, have recently emerged as tools for disease diagnosis, even for low biomarker concentrations. Detection of circulating genetic biomarkers in non-invasively collected biological fluids with NABLFAs presents an appealing and suitable method for POC testing in resource-limited regions and/or LICs. Diagnosis of breast cancer at an early stage will improve the survival rates of the patients. This review covers the analysis of the current state of NABLFA technologies used in developing countries to reduce the scourge of breast cancer.

show abstract

“…DCIS lesions are frequently positive for the expression of human epidermal growth factor receptor 2, HER-2(+), which decreases during the progression from in situ to invasive breast cancer [ 4 ]. Similarly, the estrogen receptor (ER) status changes from a predominant ER(+) state in pure DCIS to a lower percentage of ER(+) tumors as DCIS progresses and develops micro-invasions [ 5 , 6 ]. The availability of established breast ductal carcinoma in situ cell lines that resemble the genetic heterogeneity and molecular subtypes of the human disease is limited.…”

Section: Introductionmentioning

confidence: 99%

Diallyl Trisulfide Induces Apoptosis in Breast Ductal Carcinoma In Situ Derived and Minimally Invasive Breast Cancer Cells

Stan

Abtahi

2022

Nutrients

View full text Add to dashboard Cite

Breast ductal carcinoma in situ (DCIS) is a localized form of breast cancer that can progress to invasive breast cancer. Diallyl trisulfide (DATS) is a bioactive compound from Allium vegetables reported to induce anticancer effects in several cancer models. The objective of this study was to characterize DATS-induced apoptosis in breast DCIS and minimally invasive breast cancer cells. Breast DCIS cells SUM 102PT (ductal carcinoma in situ with areas of micro-invasion) and SUM 225CWN (chest wall recurrence of ductal carcinoma in situ) were used in this study. DATS induced a dose-dependent reduction in the colony formation ability of breast DCIS cells. DATS inhibited DCIS cell growth by inducing apoptosis as shown by a dose-dependent increase in cytoplasmic histone-associated DNA fragmentation. Induction of apoptosis was more pronounced in SUM 102PT cells than in SUM 225CWN cells at similar concentrations of DATS. DATS-induced apoptosis was characterized by a dose-dependent increase in cleaved poly-ADP ribose polymerase (PARP). DATS treatment resulted in an increase in the cytochrome c levels and cleavage of caspases 3, 7, and 9. This study shows that DATS inhibits cell proliferation and induces apoptosis in breast DCIS derived and minimally invasive breast cancer cells, and supports further investigation of DATS as a potential chemopreventive agent for DCIS.

show abstract

Breast ductal carcinoma in situ with micro-invasion versus ductal carcinoma in situ: a comparative analysis of clinicopathological and mammographic findings

Cited by 7 publications

References 35 publications

Manifestaciones radiológicas del carcinoma ductal <i>in situ</i>. ¿Cómo lo diagnosticamos?

Manifestaciones radiológicas del carcinoma ductal <i>in situ</i>. ¿Cómo lo diagnosticamos?

A Review of the Nucleic Acid-Based Lateral Flow Assay for Detection of Breast Cancer from Circulating Biomarkers at a Point-of-Care in Low Income Countries

Diallyl Trisulfide Induces Apoptosis in Breast Ductal Carcinoma In Situ Derived and Minimally Invasive Breast Cancer Cells

Contact Info

Product

Resources

About